Citigroup
GPCR icon

Citigroup’s Structure Therapeutics GPCR Stock Holding History

Citigroup’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$988K Buy
20,494
+13,159
+179% +$901K ﹤0.01% 3129
2025
Q4 		$510K Buy
7,335
+5,879
+404% +$240K ﹤0.01% 3562
2025
Q3 		$40.8K Sell
1,456
-144
-9% -$2.87K ﹤0.01% 4558
2025
Q2 		$33.2K Sell
1,600
-103,375
-98% -$2.27M ﹤0.01% 4944
2025
Q1 		$1.82M Buy
104,975
+30,891
+42% +$757K ﹤0.01% 2787
2024
Q4 		$2.01M Buy
74,084
+72,533
+4,677% +$2.57M ﹤0.01% 2818
2024
Q3 		$68.1K Buy
1,551
+103
+7% +$3.98K ﹤0.01% 4920
2024
Q2 		$56.9K Buy
1,448
+1,095
+310% +$45K ﹤0.01% 4506
2024
Q1 		$15.1K Sell
353
-16,327
-98% -$688K ﹤0.01% 5108
2023
Q4 		$680K Buy
16,680
+16,555
+13,244% +$949K ﹤0.01% 3165
2023
Q3 		$6.3K Buy
+125
New +$4.03K ﹤0.01% 4661

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citigroup's GPCR Position: Q1 2026 in Review

Citigroup increased its Structure Therapeutics (GPCR) stake by 179% in Q1 2026, buying an estimated $901K and bringing the position to 20,494 shares worth $988K. The position accounts for ﹤0.01% of the portfolio, ranked #3129.

Citigroup first reported a position in GPCR in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.01M in Q4 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Citigroup held 20,494 shares of Structure Therapeutics worth $988K as of Q1 2026.
  • Citigroup bought 13,159 Structure Therapeutics shares in Q1 2026, an estimated $901K.
  • Structure Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3129 holding.
  • Citigroup first reported a position in Structure Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Citigroup's Structure Therapeutics position peaked at $2.01M in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.